EIT Health · Innovation Uptake 2027

Request your free Joint Report

For a consortium led by the company commercialising a CE-marked medical device — up to €650,000, covering up to half the project costs, with a deadline of 16 September 2026. We check your eligibility against the call's own conditions and come back in writing within 2 working days, including an honest "not yet" where that is the answer.

This form is in English only, because the application itself is submitted in English. We work entirely in writing: no calls unless you ask for one. Start with the eligibility questions — if the route does not fit, we will tell you there and you can stop.

First: does the route fit?

This call has hard conditions that end an application regardless of how good the product is. Unlike most funding calls, none of them are about your last investment round — they are about your device, its CE mark, and the consortium around you. These questions check them, and take about two minutes.

As defined in regulation EU 2017/745 (MDR) or EU 2017/746 (IVDR). Products currently in transition to MDR or IVDR are also eligible — the call document says so explicitly.

An obtained CE mark at the time of submission is a hard condition of this call. If certification is close but not obtained, answer "no" — we will tell you honestly whether the timeline can work.

The call accepts IML 7 (Validation of Solution) or IML 8 (Approval & Launch) only. A rough estimate is fine — we verify it against the EIT Health framework.

Either first market deployment, or expansion into a market you are not in today. The call funds market entry and commercial piloting, not further product development.

The call requires at least two independent legal entities in different countries, covering at least two sides of the Knowledge Triangle — industry, research, education. Your company leads as the Commercialising Entity. If you have candidates in mind but nothing committed, say so — that is a normal starting point.

Your company size — it changes the conditions

Counted at the level of the commercialising company. This does not decide eligibility by itself, but it decides which conditions apply below and which sustainability agreement you would sign.

From your own resources, your partners' resources, private funding, or other grants — subject to EU double-funding rules.

The condition most people miss

Every consortium that wins this call signs a financial sustainability agreement before any money is released — and which one depends on the size of the commercialising company. A micro or small enterprise (under 50 FTE) signs a Grant-to-Options-to-Equity Agreement: EIT Health receives options over equity in the company, capped at the grant, converting at a 20% discount. A medium or large company signs a Revenue Sharing Agreement instead: the grant stays a grant, and you share revenue from the commercialised results once it passes €10,000 within 5 years, capped at the grant plus at least 15%. No shares, no options, no cap-table effect.

There is no wrong answer here, and "we need to discuss it" is the most common one.

We put this question in the intake rather than in a footnote because it is the one condition that can make an otherwise perfect fit the wrong deal. Answering "we need to discuss it" does not count against you — it is the honest answer for most companies, and it is a conversation worth having before you write anything.

Contact

Your company

EU member states and countries associated to Horizon Europe are eligible; partners can come from any eligible country. If you are unsure about yours, say so.

SME status — and with it your size class and sustainability agreement — is assessed at group level.

Including part-time staff. Under 50 FTE counts as micro/small for this call; 50 and above as medium or large.

The project

A working title is fine.

Two or three sentences in your own words. The application asks for this in a tightly limited format; we will do that compression.

MDR or IVDR class, notified body, certification dates. If you are mid-transition from MDD, describe where you stand.

Countries or segments where the solution is on the market today.

The market this project would open, and why now. Projects start on 1 January 2027 and run at most 15 months.

Names or profiles are both fine — a university group, a hospital, a research institute, a distributor. Include their country. If you have no candidates yet, describe what kind of partner the project would need.

Clinical studies, health-economics data, pilots, paying customers. This call weighs commercial and economic evidence heavily — it funds market uptake, not research.

Total project costs across the consortium, not just your share. The consortium can request up to €650,000, and that must be at most half the total.

For example national fast-track programmes, insurance contracts, tender routes, or self-pay. The call scope names reimbursement pathways explicitly — a credible route scores.

Anything else

For example a funding round in progress, a regulatory submission, or a customer commitment.

We reply in writing within 2 working days. Your answers are used only to assess this application and are never shared with third parties.

Applications are submitted on the EIT Health application platform by your consortium. We prepare the full application and hand it over for you to place and submit, with a final check before you press send. The deadline is 16 September 2026 at 16:00 CEST and is hard — late submissions are not considered.

If the route fits and you decide to proceed, a Joint Application is €9,950 — fixed, agreed before we start, with no success fee and no percentage of your grant. You bring the consortium partners; we build the full application with all of them. The Joint Report itself is free and carries no obligation.

Every condition on this page is taken from the official call document, BP2628_InnovUptake27_CallDocument_PUBLISHED_v4.pdf.